SG11201901272WA - Mesenchymal cell-derived exosomes to treat neurological disorders - Google Patents
Mesenchymal cell-derived exosomes to treat neurological disordersInfo
- Publication number
- SG11201901272WA SG11201901272WA SG11201901272WA SG11201901272WA SG11201901272WA SG 11201901272W A SG11201901272W A SG 11201901272WA SG 11201901272W A SG11201901272W A SG 11201901272WA SG 11201901272W A SG11201901272W A SG 11201901272WA SG 11201901272W A SG11201901272W A SG 11201901272WA
- Authority
- SG
- Singapore
- Prior art keywords
- tel
- aviv
- international
- ramot
- pct
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 3
- 208000025966 Neurological disease Diseases 0.000 title abstract 3
- 210000001808 exosome Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374852P | 2016-08-14 | 2016-08-14 | |
| PCT/IL2017/050899 WO2018033911A1 (en) | 2016-08-14 | 2017-08-14 | Mesenchymal cell-derived exosomes to treat neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901272WA true SG11201901272WA (en) | 2019-03-28 |
Family
ID=61196484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901272WA SG11201901272WA (en) | 2016-08-14 | 2017-08-14 | Mesenchymal cell-derived exosomes to treat neurological disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11129852B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3496730B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7014449B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109843305B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017311684B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2925527T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL264825B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3496730T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201901272WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018033911A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11648260B2 (en) | 2018-03-29 | 2023-05-16 | Technion Research And Development Foundation Limitted | Vesicles comprising a PTEN inhibitor and uses of same |
| CA3112505C (en) * | 2018-09-20 | 2023-06-20 | Citospin, S.L. | Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same |
| EP3990625A4 (en) | 2019-06-26 | 2023-07-19 | Technion Research & Development Foundation Limited | PRODUCTION OF EXTRACELLULAR VESICLES FROM STEM CELLS |
| JP6830286B1 (ja) | 2020-06-26 | 2021-02-17 | デクソンファーマシューティカルズ株式会社 | 精巣機能改善剤および精巣機能改善方法 |
| US20230210910A1 (en) | 2020-07-17 | 2023-07-06 | Dexon Pharmaceuticals Inc. | Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device |
| EP4212163A4 (en) | 2020-09-08 | 2024-09-18 | Dexon Pharmaceuticals Inc. | CYTOKINE STORM INHIBITOR, METHOD FOR USING CYTOKINE STORM INHIBITOR, AND METHOD FOR SCREENING CYTOKINE INHIBITOR |
| JP6974892B1 (ja) | 2021-05-27 | 2021-12-01 | デクソンファーマシューティカルズ株式会社 | 癌悪液質の改善剤および癌悪液質の改善方法 |
| JP7492757B2 (ja) | 2022-03-22 | 2024-05-30 | Ｄｅｘｏｎファーマシューティカルズ株式会社 | 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法 |
| US20250136992A1 (en) | 2022-05-15 | 2025-05-01 | Nurexone Biologic Ltd. | Anti-pten rna interference oligonucleotides and uses thereof |
| CN115006427A (zh) * | 2022-05-31 | 2022-09-06 | 尧舜泽生物医药(南京)有限公司 | 骨髓间充质干细胞外泌体在治疗帕金森病中的应用 |
| EP4541359A1 (en) | 2022-06-20 | 2025-04-23 | Dexon Pharmaceuticals Inc. | Ptx3 expression control agent, prophylactic drug or therapeutic drug for vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease, method for improving vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease |
| WO2023248844A1 (ja) | 2022-06-20 | 2023-12-28 | Ｄｅｘｏｎファーマシューティカルズ株式会社 | Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法 |
| CN120078807B (zh) * | 2025-02-08 | 2026-03-31 | 广东省人民医院 | 改善卵巢功能的MSC-sEVs药物及其制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US20060188496A1 (en) * | 2005-02-23 | 2006-08-24 | Hanne Bentz | Intranasal administration of active agents to the central nervous system |
| WO2008036374A2 (en) * | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| AU2009203638C1 (en) | 2008-01-04 | 2013-07-25 | Lydac Neuroscience Limited | Microvesicles |
| EP2254586B1 (en) | 2008-02-22 | 2015-04-08 | Agency For Science, Technology And Research (A*star) | Mesenchymal stem cell particles |
| KR20100054711A (ko) * | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
| CN102596177B (zh) * | 2009-07-01 | 2014-05-28 | 阿昂梅迪克斯公司 | 来源于有核哺乳动物细胞的微囊泡及其应用 |
| JPWO2011118795A1 (ja) | 2010-03-26 | 2013-07-04 | 国立大学法人名古屋大学 | 損傷部治療用組成物 |
| JP5608927B2 (ja) * | 2010-04-13 | 2014-10-22 | 国立大学法人名古屋大学 | 歯髄幹細胞を用いた神経疾患治療用組成物 |
| GB201011589D0 (en) | 2010-07-09 | 2010-08-25 | Reneuron Ltd | Therapeutic cells |
| WO2012020308A2 (en) * | 2010-08-13 | 2012-02-16 | The University Court Of The University Of Glasgow | Cellular and molecular therapies |
| WO2012068170A2 (en) * | 2010-11-15 | 2012-05-24 | Jau-Nan Lee | Generation of neural stem cells from human trophoblast stem cells |
| WO2012156968A2 (en) * | 2011-05-19 | 2012-11-22 | Ariel - University Research And Development Company, Ltd. | Use of mesenchymal stem cells for the improvement of affective and cognitive function |
| WO2013124817A2 (en) * | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | MicroRNAS FOR THE GENERATION OF ASTROCYTES |
| EP2833893B1 (en) | 2012-04-03 | 2018-08-29 | Reneuron Limited | Stem cell microparticles |
| WO2013186735A2 (en) | 2012-06-14 | 2013-12-19 | Bar-Ilan Research And Development Company Ltd. | Photothermal detection |
| WO2015038075A1 (en) * | 2013-09-16 | 2015-03-19 | Agency For Science, Technology And Research | Method |
| WO2016149358A1 (en) | 2015-03-16 | 2016-09-22 | Duncan Ross | Method of treatment comprising membrane-enclosed vesicle |
-
2017
- 2017-08-14 IL IL264825A patent/IL264825B/en unknown
- 2017-08-14 US US16/325,445 patent/US11129852B2/en active Active
- 2017-08-14 PL PL17841210.2T patent/PL3496730T3/pl unknown
- 2017-08-14 WO PCT/IL2017/050899 patent/WO2018033911A1/en not_active Ceased
- 2017-08-14 SG SG11201901272WA patent/SG11201901272WA/en unknown
- 2017-08-14 EP EP17841210.2A patent/EP3496730B1/en active Active
- 2017-08-14 AU AU2017311684A patent/AU2017311684B2/en active Active
- 2017-08-14 ES ES17841210T patent/ES2925527T3/es active Active
- 2017-08-14 JP JP2019508178A patent/JP7014449B2/ja active Active
- 2017-08-14 CN CN201780063347.2A patent/CN109843305B/zh active Active
-
2021
- 2021-08-04 US US17/394,008 patent/US20210361717A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3496730A1 (en) | 2019-06-19 |
| EP3496730B1 (en) | 2022-05-25 |
| AU2017311684A2 (en) | 2019-03-28 |
| AU2017311684B2 (en) | 2023-05-04 |
| JP7014449B2 (ja) | 2022-02-01 |
| AU2017311684A1 (en) | 2019-03-07 |
| JP2019524824A (ja) | 2019-09-05 |
| IL264825A (cg-RX-API-DMAC7.html) | 2019-04-30 |
| EP3496730A4 (en) | 2020-05-06 |
| CN109843305B (zh) | 2023-03-10 |
| US20210361717A1 (en) | 2021-11-25 |
| ES2925527T3 (es) | 2022-10-18 |
| CN109843305A (zh) | 2019-06-04 |
| US20190209621A1 (en) | 2019-07-11 |
| WO2018033911A1 (en) | 2018-02-22 |
| US11129852B2 (en) | 2021-09-28 |
| PL3496730T3 (pl) | 2022-09-26 |
| CA3033951A1 (en) | 2018-02-22 |
| IL264825B (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901272WA (en) | Mesenchymal cell-derived exosomes to treat neurological disorders | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201903427UA (en) | Deodorizing agent comprising zinc neodecanoate | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation |